Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Kevin Gardner - Managing DirectorJayson Rieger - President & CEOJohn Kirby - Interim CFOAnish Nikhanj - Senior Associate - Biotechnology Equity Research Conference Call Participants Stacy Ku - Biotechnology Equity Research AnalystSerge Belanger - Senior AnalystKemp Dolliver - Director - Research & Senior Analyst Operator Evening, ladies and gentlemen, and welcome to the Verica Pharmaceuticals First Quarter ...

Zevra Therapeutics (ZVRA) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Nichol Ochsner - Vice President of Investor Relations & Corporate CommunicationsNeil McFarlane - President & CEOJoshua Schafer - CCOR. LaDuane Clifton - CFO, Secretary & TreasurerSumant Kulkarni - Managing DirectorJason Butler - Managing Director & Biotechnology Equity ResearchEddie Hickman - Vice President Conference Call Participants Lachlan Hanbury-Brown - Biotech Equity Research Analyst Operator Good afternoon ...

Semler Scientific (SMLR) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Douglas Murphy-Chutorian - CEOEric Semler - ChairmanJennifer Herrington - Chief Operating OfficerRenae Cormier - CFO Operator Good afternoon, and welcome to the Semler Scientific First Quarter twenty twenty five Financial Results Conference Call. All participants will be in a listen only mode. After today's prepared remarks, as time permits, management will take questions submitted prior to this call via email. Plea ...

Financial Data and Key Metrics Changes - The company reported total revenue of $22,500,000 for Q1 2025, a 24% increase from $18,100,000 in Q1 2024, driven by strong growth in the RNS business [7][15] - Gross margin improved to 77% in Q1 2025 from 73.6% in Q1 2024, primarily due to increased manufacturing efficiency [16] - Net loss decreased to $6,600,000 in Q1 2025 from $8,900,000 in Q1 2024, indicating improved operational performance [18] Business Line Data and Key Metrics Changes - RNS sales increased by 26% year-over-year, and by 29% when excluding Nautilus study implants from Q1 2024 [8][15] - Sales of Dixie Medical SEEG products also contributed to revenue growth during the quarter [15] Market Data and Key Metrics Changes - The company expects a compound annual growth rate (CAGR) of over 20% through 2027, driven by RNS opportunities [14] - The company anticipates minimal revenue impact from the termination of SEEG product distribution in 2025, as remaining inventory will be sold during the transition [13] Company Strategy and Development Direction - The company is focusing on expanding access to RNS therapy, with key initiatives including Project CARE and a refocused product portfolio [8][12] - The company aims to establish the RNS system as the standard of care for drug-resistant epilepsy patients [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing strong adoption of RNS therapy and ongoing clinical development initiatives [9][14] - The company plans to achieve cash flow breakeven by the end of 2027, supported by a strengthened balance sheet following a recent equity raise [18][19] Other Important Information - The company completed a $75,000,000 follow-on equity financing, enhancing its shareholder base [8] - The company is working on expanding indications for pediatric focal epilepsy and has had discussions with the FDA regarding data from the Pediatric Epilepsy Research Consortium [11] Q&A Session Summary Question: Inquiry about gross margin performance - Management confirmed that the strong gross margin of 77% was primarily driven by the RNS business and increased production volumes [24][25][26] Question: Impact of Project CARE on referral volumes - Management noted that Project CARE has positively impacted referral volumes and implants, with increasing referrals from level three and community centers [33][35] Question: Hiring cadence throughout the year - Management indicated consistent investment in the commercial organization to support growth opportunities in core centers and new geographies [36][39] Question: Challenges in training doctors in community settings - Management stated that while support is required for new centers, the organization is experienced in training and supporting new prescribers [44][46] Question: Feedback from physicians on post-approval study data - Management reported positive feedback from physicians regarding the compelling data presented, which is expected to drive engagement and sales [57][60] Question: Exit from Dixie Medical and its implications - Management acknowledged the loss of visibility in the diagnostic process but emphasized the importance of leveraging existing relationships to maintain patient care quality [78][82]

NEXGEL (NXGL) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Valter Pinto - Managing DirectorAdam Levy - CEO, President & DirectorJoseph F. McGuire - CFOEric Ramos - Student Portfolio Manager Conference Call Participants Naz Rahman - AnalystNone - Analyst Operator Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NextGel's First Quarter twenty twenty five Financial Results Conference Call. I will now turn the call over to Walter ...

Vaxart (VXRT) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Edward Berg - Senior Vice President and General CounselSteven Lo - CEO , President & DirectorJames Cummings - Chief Medical OfficerSean Tucker - Founder & Chief Scientific OfficerPhillip Lee - Chief Financial OfficerCheng Li - Director - Equity ResearchMayank Mamtani - Senior Managing Director & Group Head of HealthcareLiang Cheng - Senior Research Associate Operator Greetings. Welcome to Vaxart Business Update and First Quart ...

Daré Bioscience (DARE) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting OfficerSabrina Johnson - President, CEO & DirectorDouglas Tsao - Managing DirectorLeona Nease - Biotech Equity Research AssociateWill Hidell - Equity Research Associate Operator Welcome to the conference call hosted by Dare Bioscience to review the company's First Quarter twenty twenty five Financial Results and to provide a business update. This call is being recorded. My name ...

Seer (SEER) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the SEER First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please pr ...

Intellicheck (IDN) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Gar Jackson, Investor Relations. Thank you, sir. You may begin. Speaker1 Thank you, operator. Good afternoon, and thank you for joining us today for the Intellicheck first Quarter twenty twenty five Earnings Call. Before we get started, I will take a few minutes to read the forward looking statement. Certain statements in this conference c ...

Financial Data and Key Metrics Changes - The company generated $29 million in revenue for the first quarter of 2025, with only two months of operations at Chivo, North Dakota [6][21] - Combined operating revenue and other net income was $30.9 million for the first quarter [21] - The company ended the quarter with $135 million in cash, cash equivalents, and restricted cash [21] Business Line Data and Key Metrics Changes - The RNG subsidiary generated $5.7 million in revenue during the quarter, reflecting a $1.7 million increase compared to the previous year, driven by increased LCFS credit generation [21][22] - At Gevo North Dakota, income from operations was $500,000, and adjusted EBITDA was $1.8 million for February and March [22] - Gevo RNG reported income from operations of $1.1 million and adjusted EBITDA of $2.7 million last quarter [22] Market Data and Key Metrics Changes - The carbon intensity score for the company's ethanol is approximately 20, with expectations to improve further [10][21] - The company captured and sequestered 29,000 metric tons of carbon dioxide at the North Dakota site, avoiding 7,000 metric tons of carbon emissions [26] Company Strategy and Development Direction - The company aims to become EBITDA positive this year, leveraging the acquisition of the North Dakota plant and the monetization of the 45Z tax credit [7][21] - Plans to develop an alcohol-to-jet (ATJ) plant in North Dakota, with expectations for faster construction and lower capital costs [12][13] - The company is pursuing opportunities to develop and deploy ATJ plant designs globally, focusing on partnerships rather than full ownership [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fundamentals of the business despite market noise, indicating a strong growth trajectory [20] - The company anticipates monetizing the 45Z tax credits soon, which could significantly enhance EBITDA [8][56] - Management highlighted the importance of domestic energy production, job creation, and supporting agriculture as part of their mission [33] Other Important Information - The company is actively negotiating its first 45Z tax credit sales and expanding its market position for durable carbon dioxide removal credits [28][30] - The ATJ project is expected to be economically advantageous compared to traditional jet fuel production methods [17][18] Q&A Session Summary Question: How should we think about the cash cadence for the year? - The company plans to spend less than $40 million on the ATJ-sixty project and is refinancing its RNG plant to free up cash [40][41] Question: Is there an established market for carbon abatement products? - There is a growing market for durable carbon dioxide removals, and the company is expanding its presence in this area [51][52] Question: Are you potentially going to start monetizing the 45Z credits in Q2? - The company expects to monetize the 45Z credits soon and aims to be EBITDA positive for the year [56][57] Question: Could you speak to the amount you expect to receive for ethanol and dairy RNG molecules? - The expected value is proportional to the carbon intensity scores, with potential earnings of about $2 per CI point [68][70] Question: Can you provide a range for the value of Scope 1 and Scope 3 emission credits? - The values are well north of the types of carbon value seen in LCFS markets, potentially in the hundreds of dollars per ton [88][90]